Azygos Vascular

The HFpEF Crisis 

The Problem

A silent epidemic affecting over 30 million people, representing half of all heart failure cases.

Prognosis is grim, with a 5-year mortality rate (~50%) worse than many cancers.

Frequently misdiagnosed as normal aging, leading to delayed and ineffective treatment.

Treatment Limitations

A major unmet clinical need with few therapies that fundamentally alter the disease.

Current treatments mostly manage symptoms (like fluid overload) instead of the root cause: a stiff heart muscle.

Proven drugs for other types of heart failure have consistently failed in large-scale HFpEF trials.

Patient Impact

Debilitating breathlessness makes simple daily tasks exhausting.

Creating a "shrinking world" of lost independence, social isolation, and depression.

Patients live in constant fear of sudden flare-ups, leading to frequent, traumatic hospitalizations.